2020
The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer
Ranasinghe W, Chapin B, Kim I, Sooriakumaran P, Lawrentschuk N. The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer. BJU International 2020, 125: 792-800. PMID: 32176456, DOI: 10.1111/bju.15055.Peer-Reviewed Original ResearchConceptsHormone-sensitive metastatic prostate cancerMetastatic prostate cancerCytoreductive prostatectomyAndrogen deprivation therapyProstate cancerOverall survivalRadical prostatectomyLimited bone metastasesCancer-specific outcomesLocal treatment optionsProgression-free survivalDiagnosis of metastasisPrimary outcome measureNovel treatment algorithmOligometastatic settingAdjuvant treatmentMetastatic settingSecondary endpointsCastration resistanceMetastatic diseaseStandard therapyBone metastasesDefinitive treatmentOngoing trialsTreatment algorithm
2019
Immune reaction by cytoreductive prostatectomy.
Lee G, Srivastava A, Kwon Y, Kim I. Immune reaction by cytoreductive prostatectomy. American Journal Of Clinical And Experimental Urology 2019, 7: 64-79. PMID: 31139701, PMCID: PMC6526355.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerCytoreductive prostatectomyProstate cancerMetastatic diseaseCastration-resistant prostate cancerCommon non-cutaneous cancerCastration-resistant diseaseResistant prostate cancerMale cancer deathsNon-cutaneous cancerNovel treatment strategiesImmunologic changesAdvanced diseaseOncologic outcomesSurvival benefitCombinational immunotherapyCancer deathTreatment modalitiesHormonal manipulationMetastatic cancerTreatment strategiesImmune reactionsSurvival rateEffective cureCancer
2016
Chapter 52 Androgen Deprivation Therapy: Appropriate Patients, Timing to Initiate ADT, and Complications
Salmasi A, Patel N, Kim I. Chapter 52 Androgen Deprivation Therapy: Appropriate Patients, Timing to Initiate ADT, and Complications. 2016, 481-489. DOI: 10.1016/b978-0-12-800077-9.00052-9.Peer-Reviewed Original ResearchAndrogen deprivation therapyProstate cancerIntermittent androgen deprivation therapyMetastatic prostate cancer treatmentAndrogen-dependent natureProstate cancer treatmentQuality of lifeCost of treatmentDeprivation therapyAdjuvant treatmentMetastatic diseaseADT useAppropriate patientsMetabolic abnormalitiesPalliative optionSignificant complicationsRadical prostatectomyPotential complicationsBone densitySide effectsTreatment settingsOrgan systemsComplicationsOptimal timingCancer treatment
2015
Lower Levels of Human MOB3B Are Associated with Prostate Cancer Susceptibility and Aggressive Clinicopathological Characteristics
Kim E, Kim Y, Kang H, Yoon H, Kim W, Kim Y, Yun S, Moon S, Choi Y, Kim I, Lee S, Kim W. Lower Levels of Human MOB3B Are Associated with Prostate Cancer Susceptibility and Aggressive Clinicopathological Characteristics. Journal Of Korean Medical Science 2015, 30: 937-942. PMID: 26130958, PMCID: PMC4479949, DOI: 10.3346/jkms.2015.30.7.937.Peer-Reviewed Original ResearchConceptsProstate cancerClinicopathological characteristicsElevated prostate-specific antigen levelsProstate-specific antigen levelBenign prostatic hyperplasia patientsNon-metastatic diseaseAggressive clinicopathologic featuresLow PSA levelsSpecific antigen levelsProstatic hyperplasia patientsAggressive clinicopathological characteristicsLow Gleason scoreHuman prostate cancerCharacteristic curve analysisProstate cancer susceptibilityPSA levelsMetastatic diseasePCa patientsClinicopathologic featuresHyperplasia patientsAntigen levelsGleason scoreClinicopathological parametersPCa tissuesReal-time PCR
2014
Cytoreductive prostatectomy: Evidence in support of a new surgical paradigm (Review)
FAIENA I, SINGER E, PUMILL C, KIM I. Cytoreductive prostatectomy: Evidence in support of a new surgical paradigm (Review). International Journal Of Oncology 2014, 45: 2193-2198. PMID: 25340386, PMCID: PMC4215584, DOI: 10.3892/ijo.2014.2656.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancerProstate cancerMetastatic diseaseSystemic therapyRadical prostatectomyPotential oncologic benefitsDefinitive local therapyPrior radical prostatectomyLow-stage cancersNew surgical paradigmOncologic benefitAcceptable morbidityAdvanced diseaseMetastatic settingLocal therapySimilar morbidityCancer deathKidney cancerStage cancerBetter survivalSurgical paradigmPatientsCancerPotential benefitsTherapy
2013
Cancer-specific Survival After Metastasis Following Primary Radical Prostatectomy Compared with Radiation Therapy in Prostate Cancer Patients: Results of a Population-based, Propensity Score–Matched Analysis
Shao Y, Kim S, Moore D, Shih W, Lin Y, Stein M, Kim I, Lu-Yao G. Cancer-specific Survival After Metastasis Following Primary Radical Prostatectomy Compared with Radiation Therapy in Prostate Cancer Patients: Results of a Population-based, Propensity Score–Matched Analysis. European Urology 2013, 65: 693-700. PMID: 23759328, PMCID: PMC3825778, DOI: 10.1016/j.eururo.2013.05.023.Peer-Reviewed Original ResearchConceptsProstate cancer-specific survivalCancer-specific survivalPrimary radical prostatectomyRadical prostatectomyRT groupRadiation therapyProstate cancerIntermediate-high riskRisk of PCSMCancer-specific mortalityEnd Results-MedicarePrimary radiation therapyPropensity-matched cohortLow-risk patientsPrimary treatment modalityLocalized prostate cancerProstate cancer patientsDevelopment of metastasesOnset of metastasisResidual confoundersHazard ratioMetastatic diseaseRisk patientsClinical courseSurveillance EpidemiologyDetailed Analysis of Patients with Metastasis to the Prostatic Anterior Fat Pad Lymph Nodes: A Multi-Institutional Study
Kim I, Modi P, Sadimin E, Ha Y, Kim J, Skarecky D, Cha D, Wambi C, Ou Y, Yuh B, Park S, Llukani E, Albala D, Wilson T, Ahlering T, Badani K, Ahn H, Lee D, May M, Kim W, Lee D. Detailed Analysis of Patients with Metastasis to the Prostatic Anterior Fat Pad Lymph Nodes: A Multi-Institutional Study. Journal Of Urology 2013, 190: 527-534. PMID: 23485503, DOI: 10.1016/j.juro.2013.02.073.Peer-Reviewed Original ResearchConceptsProstatic anterior fat padAnterior fat padLymph node metastasisMetastatic diseaseLymph nodesNode metastasisFat padPathological analysisMost patientsConcomitant pelvic lymph node dissectionPelvic lymph node dissectionBiochemical recurrence-free survivalAdjuvant/salvage therapyLymph node dissectionCharacteristics of patientsHigh-risk featuresTertiary care centerRecurrence-free survivalMulti-institutional studyPerioperative characteristicsSalvage therapyAdjuvant therapyNode dissectionAndrogen ablationClinical outcomes
2012
Transcriptional repression of RUNX2 is associated with aggressive clinicopathological outcomes, whereas nuclear location of the protein is related to metastasis in prostate cancer
Yun S, Yoon H, Bae S, Lee O, Choi Y, Moon S, Kim I, Kim W. Transcriptional repression of RUNX2 is associated with aggressive clinicopathological outcomes, whereas nuclear location of the protein is related to metastasis in prostate cancer. Prostate Cancer And Prostatic Diseases 2012, 15: 369-373. PMID: 22890388, DOI: 10.1038/pcan.2012.31.Peer-Reviewed Original ResearchConceptsMetastatic diseaseGleason scoreProstate cancerMRNA expressionElevated PSA levelsNon-metastatic diseaseCase-control studyLow Gleason scoreRunx2 expressionHuman prostate tissuePSA levelsBPH patientsClinicopathological characteristicsClinicopathological outcomesCommon cancerLower PSAPrognostic markerReal-time PCRImmunohistochemical stainingImmunohistochemical analysisTranscription factor 2BPH controlProstate tissueRunx2 mRNA expressionCaP aggressiveness
2011
The hOGG1 mutant genotype is associated with prostate cancer susceptibility and aggressive clinicopathological characteristics in the Korean population
Yun S, Ha Y, Chae Y, Kim J, Kim I, Kim W. The hOGG1 mutant genotype is associated with prostate cancer susceptibility and aggressive clinicopathological characteristics in the Korean population. Annals Of Oncology 2011, 23: 401-405. PMID: 21515665, DOI: 10.1093/annonc/mdr115.Peer-Reviewed Original ResearchConceptsAggressive clinicopathological characteristicsClinicopathological characteristicsGleason scoreHOGG1 codon 326 genotypesBenign prostatic hyperplasia patientsSer/Ser genotypeProstatic hyperplasia patientsCase-control studyRisk of CaPPeptide nucleic acid-mediated PCR clampingSer/CysProstate cancer susceptibilityWild-type genotypeCAP patientsMetastatic diseaseClinicopathological outcomesHyperplasia patientsTumor stageProstate cancerHigh riskHOGG1 genotypePatientsSer alleleCys alleleKorean population
2001
Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy.
Shariat S, Shalev M, Menesses-Diaz A, Kim I, Kattan M, Wheeler T, Slawin K. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. Journal Of Clinical Oncology 2001, 19: 2856-64. PMID: 11387358, DOI: 10.1200/jco.2001.19.11.2856.Peer-Reviewed Original ResearchConceptsProstate cancer metastaticPlasma TGFPreoperative plasma levelsRegional lymph nodesRadical prostatectomyCancer metastaticPSA progressionLymph nodesGleason sumPlasma levelsGrowth factorLocal-only failureOccult metastatic diseasePathologic Gleason sumPostoperative multivariate analysisOrgan-confined diseaseSurgical margin statusLymph node metastasisBiopsy Gleason sumRadical prostatectomy patientsProstate cancer invasionMetastatic diseaseBone metastasesConsecutive patientsMargin status